Literature DB >> 6359986

In vitro response of murine alveolar and peritoneal macrophages to Mycobacterium intracellulare.

P R Gangadharam, P F Pratt.   

Abstract

Normal resident and BCG-activated alveolar and peritoneal macrophages from female Swiss Webster mice were compared for their ability to ingest and subsequently control the multiplication of Mycobacterium intracellulare in vitro. Resident peritoneal macrophages failed from the moment of ingestion to control the multiplication of engulfed bacilli resulting in host cell lysis, whereas activated peritoneal macrophages and both resident and activated alveolar macrophages constrained bacterial division for at least 7 days before comparable bacterial multiplication led to phagocyte death. The number of bacilli needed to lyse a macrophage was impossible to determine precisely because viable macrophages commonly contained several hundred mycobacteria. Minimal intracellular bacterial generation times were 20 h for each macrophage type. Differences in the rates of bacterial phagocytosis between both macrophage types, either resident or activated, are intrinsic properties of the macrophages and were not induced by the mycobacteria, because the same patterns of particle ingestion were observed after exposure to latex microspheres.

Entities:  

Mesh:

Year:  1983        PMID: 6359986     DOI: 10.1164/arrd.1983.128.6.1044

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  16 in total

1.  Intramacrophage growth of Mycobacterium avium during infection of mice.

Authors:  C Frehel; C de Chastellier; C Offredo; P Berche
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

2.  Binding of Mycobacterium avium-Mycobacterium intracellulare to human leukocytes.

Authors:  A Catanzaro; S D Wright
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

3.  Enhanced intramacrophage activity of resorcinomycin A against Mycobacterium avium-Mycobacterium intracellulare complex after liposome encapsulation.

Authors:  R Gomez-Flores; R Hsia; R Tamez-Guerra; R T Mehta
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

4.  Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice.

Authors:  N Düzgüneş; V K Perumal; L Kesavalu; J A Goldstein; R J Debs; P R Gangadharam
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

5.  Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase.

Authors:  T Hayashi; S P Rao; K Takabayashi; J H Van Uden; R S Kornbluth; S M Baird; M W Taylor; D A Carson; A Catanzaro; E Raz
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

6.  Mycobacterium avium-intracellulare contamination of mammalian cell cultures.

Authors:  I H Lelong-Rebel; Y Piemont; M Fabre; G Rebel
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-10-15       Impact factor: 2.416

7.  Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation.

Authors:  Mauricio Alvarez; Carolyn Saylor; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2008-04-01       Impact factor: 3.715

8.  Superoxide dismutase activity of Mycobacterium avium, M. intracellulare, and M. scrofulaceum.

Authors:  B K Mayer; J O Falkinham
Journal:  Infect Immun       Date:  1986-09       Impact factor: 3.441

9.  Growth of Mycobacterium avium in activated macrophages harvested from inbred mice with differing innate susceptibilities to mycobacterial infection.

Authors:  R W Stokes; F M Collins
Journal:  Infect Immun       Date:  1988-09       Impact factor: 3.441

10.  Activity of amikacin against Mycobacterium avium complex under simulated in vivo conditions.

Authors:  P R Gangadharam; L Kesavalu; P N Rao; V K Perumal; M D Iseman
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.